What Does Indivior (INDV) Do? – Stock Outlook, Earnings, Market Cap, Related Stocks, and Headquarters Overview
Indivior (INDV) is a specialty pharmaceutical company that develops and sells opioid use disorder treatments. As a stock whose earnings and share price are driven by the growth of its monthly injectable therapy SUBLOCADE, addiction treatment demand, and the competitive landscape, there is significant investor interest in its outlook and related stocks.
Indivior (INDV) is a specialty pharmaceutical company that develops and sells treatments for opioid use disorder. Headquartered in the US and Europe, it supplies the monthly injectable therapy SUBLOCADE as well as sublingual film treatments, securing a leading position in the opioid use disorder treatment market.
With opioid use disorder treatment as its core business, Indivior markets SUBLOCADE, a once-monthly long-acting injectable, along with sublingual film treatments. SUBLOCADE has established itself as a widely prescribed long-acting injectable in the US, securing a leading position in the specialized field of addiction treatment.
💰 How does Indivior make money?
| Business Segment | Revenue Mix | Description |
|---|---|---|
| SUBLOCADE | Flagship | Once-monthly injectable addiction treatment |
| Sublingual Film | Core Growth Driver | Sublingual film addiction treatment |
| Pipeline & Others | Diversification Pillar | New therapy pipeline |
Recent revenue has been driven primarily by the growth of SUBLOCADE, the once-monthly injectable, supported by an expanding patient base and the adoption of new administration protocols. The sublingual film treatment has seen a gradual decline in contribution due to generic competition, making the transition to long-acting injectables a key strategy. Prescription expansion, insurance coverage, and the entry of competing treatments are the core variables shaping earnings performance.
📐 Indivior Market Cap and Company Scale
The market capitalization stands at $4.9B with a workforce of 838명.
As a leading specialty pharmaceutical company in opioid use disorder treatment, Indivior occupies a comparable position alongside ALKS (Alkermes), COLL (Collegium), and TEVA (Teva) within the specialty pharma space. It has secured a differentiated position in the long-acting injectable segment and is pursuing growth through expanded SUBLOCADE prescriptions.
📈 Indivior Outlook and Stock Price Trends
Structural growth in opioid use disorder treatment demand, SUBLOCADE prescription expansion, and the introduction of new administration protocols are the key medium- to long-term growth drivers. The shift toward long-acting injectables and new indications/pipeline opportunities broaden the growth runway, while expanded insurance coverage improves patient access. On the other hand, near-term risks include generic competition in sublingual films, the entry of competing treatments, changes in reimbursement rates and policy, and high dependence on a single product, all of which can drive volatility.
- SUBLOCADE prescription expansion
- Shift to long-acting injectables
- New indications and pipeline
⚔️ Indivior Key Competitive Strengths and Risks
A leading position in the long-acting injectable segment and exposure to structurally growing addiction treatment demand are the core strengths, while single-product dependence and generic/competing treatments are the key risks.
💪 Key Competitive Strengths
⚠️ Key Risks
🔄 Indivior Competitors and Related Stocks (Beneficiaries)
Peers commonly compared within the specialty pharmaceutical space include ALKS (Alkermes), which markets addiction treatments; COLL (Collegium), focused on pain and addiction therapy; and TEVA (Teva), spanning generics and specialty pharma. Related names grouped under the specialty pharma theme include JAZZ (Jazz Pharmaceuticals) and PCRX (Pacira BioSciences), which share exposure to novel drug prescriptions and the reimbursement environment.
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
 ALKS | Alkermes plc | $48.99 | -2.1% | $8.2B | 127.3 | 4.5 | 3.85% | - |
 COLL | Collegium Pharmaceutical Inc | $35.39 | -1.6% | $1.1B | 17.3 | 3.7 | 27.41% | - |
| TEVA | Teva- Pharmaceutical Industries Ltd ADR | $35.01 | -1.1% | $40.8B | 58.9 | 5.3 | 9.6% | - |
| 종목 | 회사명 | 가격 | 등락 | 시총 | PER | PBR | ROE | 배당률 |
|---|---|---|---|---|---|---|---|---|
 JAZZ | Jazz Pharmaceuticals plc | $252.86 | -2.1% | $15.9B | - | 3.5 | 0.68% | - |
 PCRX | Pacira BioSciences Inc | $26.38 | -2.2% | $1.0B | 211.2 | 1.6 | 0.71% | - |
✅ Investor Checklist for Indivior
Key checkpoints for Indivior investors: SUBLOCADE prescription expansion, generic competition in sublingual films, the entry of competing treatments, and insurance coverage and policy conditions are the core short- to medium-term variables.
| Checkpoint | What to Verify | Current Status |
|---|---|---|
| 💉 Prescription Expansion | SUBLOCADE prescriptions and patient count | Growth trend |
| ⚔️ Competition | Generic and competing therapy trends | Needs monitoring |
| 🏥 Insurance Coverage | Insurance coverage and reimbursement environment | Needs monitoring |
| 🔬 Pipeline | New indications and pipeline | In progress |
Given the high dependence on flagship products, any slowdown in SUBLOCADE prescriptions can have an outsized impact on earnings—this is the central risk. Generic competition in sublingual films, the entry of competing long-acting treatments, and reimbursement/policy changes can also act as revenue swing factors.
Indivior is a leading specialty pharmaceutical company in the long-acting opioid use disorder treatment segment, with SUBLOCADE prescription expansion and structural demand serving as key strengths. However, given single-product dependence and intensifying competition, a phased buying approach with a long-term perspective is recommended.
이 글은 2026년 6월 7일 기준 정보입니다.